VEGF is currently regarded as a possible target for novel therapies for psoriasis as some authors showed that bevacizumab, a monoclonal antibody against VEGF, determined complete remission of psoriasis lesions in a patient treated for colon cancer [65]. This evidence concerns the gene VEGFA and colonic neoplasm.